Celltrion Decides on Additional Share Buyback Worth 100 Billion Won

Comprehensive Efforts Continue to Enhance Corporate Value

Celltrion announced on the 17th that its board of directors has decided to conduct an additional share buyback worth approximately 100 billion won. The buyback will be carried out through on-market purchases starting on the 18th, with plans to complete the acquisition within this year.

Celltrion continues to make decisions on share buybacks, believing that the company's intrinsic value is undervalued in the market compared to its growth potential. The company has prioritized stabilizing its stock price and enhancing shareholder value, and is consistently implementing shareholder-friendly policies such as share buybacks and cancellations.

Including this latest decision, the total value of share buybacks conducted over nine rounds this year amounts to approximately 850 billion won, while the value of share cancellations has reached about 900 billion won.

The holding company, affiliates, and employees-including top management-are also actively supporting efforts to maximize shareholder value across the group.

Celltrion Holdings completed a buyback of Celltrion shares worth about 120 billion won by early June this year and is now pursuing an additional share purchase plan worth 500 billion won. Of this, shares worth 262 billion won were acquired by September, and the company recently announced a further buyback plan worth 125 billion won, with acquisitions set to begin early next month. The remaining portion of the planned 500 billion won, about 125 billion won, is also scheduled to be acquired by the end of the year.

Previously, Seo Jungjin, Chairman of Celltrion Group, and Celltrion Skincure each purchased shares worth 50 billion won on the open market by July, further supporting shareholder value. Employees also participated by purchasing company shares worth about 40 billion won through the employee stock ownership plan.

A Celltrion representative stated, "The decision for an additional share buyback demonstrates our confidence in the company's intrinsic value and future growth potential," adding, "We will do our best to enhance shareholder value by realizing long-term growth potential through increased revenue from the sequential launch of follow-up biosimilar products and achievements in new drug development, thereby strengthening our global competitiveness."

This content was produced with the assistance of AI translation services.